FDA response on IL 13-PE expected on February 4, 2010 (NASDAQ:NEOL)
On January 4, 2010, NeoPharm, Inc. (NASDAQ:NEOL.PK), a biopharmaceutical company that discovers, develops and markets drugs for treating patients suffering from cancer and other life threatening diseases, disclosed that it has submitted an investigational new drug application (IND) to the FDA. The application was submitted for the IL 13-PE38QQR (also called IL 13-PE for short), [...]
Continue reading...FDA Response Expected Expected Soon for Bovie (AMEX:BVX)
4 February 2010
Comments Off
On August 3, 2009, Bovie Medical Corporation (AMEX:BVX) announced that it has submitted a 510(K) to the FDA, for its ICON VS electrosurgical generator, in order to obtain pre-market approval. We hope the company will get a response from the FDA after 6 months, around February 3, 2010.
Continue reading...Complete Results of Phase 2 trial of Biomoda’s Lung Cancer Test Anticipated (NASDAQ:BMOD)
1 February 2010
Comments Off
Biomoda, Inc. (NASDAQ:BMOD.OB), whose headquarter is in Albuquerque, New Mexico, is a company that discovers and develops precise, safe and cheap in-vitro tests that diagnose cancer in the early stage – the period of time when it is most possible for treatment methods to cure the cancer or to stop the cancer from getting worse.
Continue reading...Article on Perifosone’s Phase 2 trial to be published (NASDAQ:KERX)
1 February 2010
Comments Off
KRX-0401 (which is more popularly known by its generic name perifosone) is an anti-cancer drug that has been discovered and developed by Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Keryx, which has its headquarters in the New York City, acquires, develops and commercializes pharmaceutical drugs that can cure or improve the conditions of people suffering from fatal diseases, [...]
Continue reading...Clinical Trial Results for H1N1 Vaccine Expected Soon (NASDAQ:NVAX)
30 January 2010
Comments Off
On December 2, 2009 Novavax, Inc. (NASDAQ:NVAX) announced that it has received encouraging primary data from the first stage of the Phase 2 trial. The trial is being carried out on the company’s newly developed vaccine that is intended to be used to get immunogenicity from H1N1 virus like particle (VLP) pandemic influenza, which is [...]
Continue reading...FDA’s response on Troponin Assay Anticipated (NASDAQ:NSPH)
30 January 2010
Nanosphere Inc. (NASDAQ:NSPH) is a pharmaceutical company that develops, manufactures and then brings into market “advanced molecular diagnostics systems†which detect “multiplexed direct genomic and ultra-sensitive protein detectionâ€. All its products are based on the company’s trademark Verigone(R) system. It has developed troponin assay especially for the flu season and has submitted an application to [...]
Continue reading...AspenBio Pharma’s Meeting with FDA anticipated Soon (NASDAQ:APPY)
30 January 2010
Comments Off
On December 29, 2009, AspenBio Pharma, Inc. (NASDAQ: APPY), which is a growing bio science company that develops innovative tests and drugs for the betterment of mankind, disclosed information about the Premarket Notification 510(K) that it had submitted to the United States of America’s toughest regulator the Food & Drug Administration.
Continue reading...Results of XL765 Clinical Trial Expected on January 31 (NASDAQ:EXEL)
30 January 2010
Comments Off
On June 1, 2009, Exelixis, Inc. (NASDAQ:EXEL) announced that they received favorable results from the Phase 1 trial of XL765. The trial dealt with finding the effects of increasing the dose of XL765. XL765 is an innovative drug that is being co-developed by Exelixis Inc. and Sanofi Aventis. Â
Continue reading...More details of Phase 2 trial of TH-302 expected soon(NASDAQ:THLD)
30 January 2010
Comments Off
Hypoxia Activated Prodrug (also called HAP in short) is a type of anti cancer drug that is used by patients suffering from Tumor Hypoxia. This is condition where there is a lack of oxygen in the tumor cells. Hypoxia Activated Prodrug drugs treat levels of hypoxia (that is, low levels of oxygen) found in tumor [...]
Continue reading...Merck hopes to resubmit the NDA for Cladribine January 31 (NASDAQ:MKGAY)
30 January 2010
Comments Off
Cladribine Tablets is a drug for young adults, especially females, who are suffering from multiple sclerosis (MS), which is a neurological disorder that affects the nerve cells in the spinal cord and the brain. The drug has been developed by Merck KGaA (NASDAQ:MKGAY.PK). Merck KGaA is a German-based pharmaceutical company.
Continue reading...
4 February 2010
View Comments